Abstract Title:

Modulatory effect of myricitrin against chromosome instability and cytostasis induced by bleomycin and oxaliplatin in CHO-K1 cells.

Abstract Source:

Drug Chem Toxicol. 2022 Jun 14:1-10. Epub 2022 Jun 14. PMID: 35702048

Abstract Author(s):

Ana Paula de Souza, Raíne Fogliati Schardosim, Juliana Escouto Al Kateeb, Mauricio Lehmann, Ivana Grivicich, Rafael Rodrigues Dihl

Article Affiliation:

Ana Paula de Souza


Myricitrin (MYR), a flavonol consumed in the leaves and fruits of plants of thefamily, presents anti-proliferative, anti-inflammatory, anti-diabetic, and antioxidant properties in humans. However, there are few studies regarding the cyto-genotoxicity and the chemopreventive potential of MYR. Using theMicronucleus test, the cytostasis, mutagenicity, and modulatory effect of MYR in CHO-K1 cells were assessed. The concentrations of 39 and 78 µg/mL ( < 0.001.) of MYR decrease the cytokinesis-block proliferation index (CBPI) in the short exposure treatment (4 h), while in the extended treatment (24 h), concentrations of 4.8, 9.7, 19.5, 39 and 78 µg/mL ( < 0.001.) decreased the CBPI. MYR associated with oxaliplatin decreased CBPI at all tested concentrations in the pre-( < 0.001) and post-treatments ( < 0.001), but there was no decrease when associated with bleomycin. As for chromosome instability, MYR did not increase the frequency of micronuclei (MNi), nucleoplasmic bridges (NPBs), or nuclear buds (NBUDs) in the 4 h exposure time, however, in the 24 h treatment, MYR increased the frequencyof MNi and NPBs at concentration 19.5 µg/mL ( < 0.001). As for the modulatory effect, MYR associated with bleomycin decreased the frequency of MNi, NPBs, and NBUDs at all concentrations in the pretreatment (MNi and NPBs < 0.001, NBUDs < 0.05) and simultaneously (MNi, NPBs and NBUDs < 0.001). When associated with oxaliplatin, the simultaneous treatment decreased the frequency of MNi ( < 0.001) and NBUDs ( < 0.01) at all concentrations, however, in the post-treatment, MYR increased MNi ( < 0.001) and NPBs < 0.05) in CHO-K1 cells, when compared to oxaliplatin alone. The results demonstrated that MYR could modulate the mutagenic and cytostatic actions of bleomycin and oxaliplatin, demonstrating distinct behaviors, depending on the mechanism of action of the chemotherapeutic agent.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.